Nanhua Bio Medicine Co Ltd - Asset Resilience Ratio
Nanhua Bio Medicine Co Ltd (000504) has an Asset Resilience Ratio of 11.81% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Nanhua Bio Medicine Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1993–2024)
This chart shows how Nanhua Bio Medicine Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Nanhua Bio Medicine Co Ltd balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Nanhua Bio Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 000504 current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥120.00 Million | 11.81% |
| Total Liquid Assets | CN¥120.00 Million | 11.81% |
Asset Resilience Insights
- Moderate Liquidity: Nanhua Bio Medicine Co Ltd has 11.81% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Nanhua Bio Medicine Co Ltd Industry Peers by Asset Resilience Ratio
Compare Nanhua Bio Medicine Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Nanhua Bio Medicine Co Ltd (1993–2024)
The table below shows the annual Asset Resilience Ratio data for Nanhua Bio Medicine Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.10% | CN¥607.89K ≈ $88.95K |
CN¥608.17 Million ≈ $88.99 Million |
-0.12pp |
| 2023-12-31 | 0.22% | CN¥1.72 Million ≈ $251.45K |
CN¥771.38 Million ≈ $112.88 Million |
-0.08pp |
| 2022-12-31 | 0.30% | CN¥1.69 Million ≈ $246.59K |
CN¥553.06 Million ≈ $80.93 Million |
+0.23pp |
| 2021-12-31 | 0.08% | CN¥501.82K ≈ $73.43K |
CN¥659.25 Million ≈ $96.47 Million |
-0.04pp |
| 2020-12-31 | 0.12% | CN¥657.31K ≈ $96.19K |
CN¥556.14 Million ≈ $81.38 Million |
-0.24pp |
| 2019-12-31 | 0.36% | CN¥961.86K ≈ $140.75K |
CN¥268.33 Million ≈ $39.27 Million |
+0.04pp |
| 2018-12-31 | 0.32% | CN¥1.09 Million ≈ $158.85K |
CN¥342.71 Million ≈ $50.15 Million |
-0.03pp |
| 2017-12-31 | 0.35% | CN¥1.41 Million ≈ $206.03K |
CN¥404.78 Million ≈ $59.23 Million |
-0.22pp |
| 2016-12-31 | 0.56% | CN¥1.70 Million ≈ $248.19K |
CN¥301.19 Million ≈ $44.07 Million |
-2.06pp |
| 2012-12-31 | 2.62% | CN¥1.99 Million ≈ $291.59K |
CN¥76.06 Million ≈ $11.13 Million |
+1.78pp |
| 2011-12-31 | 0.84% | CN¥2.33 Million ≈ $341.54K |
CN¥276.47 Million ≈ $40.46 Million |
-0.30pp |
| 2010-12-31 | 1.14% | CN¥3.28 Million ≈ $479.91K |
CN¥286.82 Million ≈ $41.97 Million |
+0.37pp |
| 2009-12-31 | 0.77% | CN¥3.18 Million ≈ $465.74K |
CN¥412.24 Million ≈ $60.32 Million |
+0.50pp |
| 2008-12-31 | 0.27% | CN¥1.47 Million ≈ $215.32K |
CN¥536.52 Million ≈ $78.51 Million |
-0.69pp |
| 2007-12-31 | 0.96% | CN¥6.54 Million ≈ $957.26K |
CN¥681.31 Million ≈ $99.70 Million |
-1.37pp |
| 2006-12-31 | 2.33% | CN¥14.86 Million ≈ $2.17 Million |
CN¥637.48 Million ≈ $93.28 Million |
+0.58pp |
| 2005-12-31 | 1.75% | CN¥11.34 Million ≈ $1.66 Million |
CN¥648.02 Million ≈ $94.83 Million |
-0.05pp |
| 2004-12-31 | 1.80% | CN¥10.87 Million ≈ $1.59 Million |
CN¥603.88 Million ≈ $88.37 Million |
+1.20pp |
| 2003-12-31 | 0.60% | CN¥3.56 Million ≈ $521.12K |
CN¥595.75 Million ≈ $87.18 Million |
+0.13pp |
| 2002-12-31 | 0.47% | CN¥2.90 Million ≈ $424.82K |
CN¥620.07 Million ≈ $90.74 Million |
+0.01pp |
| 2001-12-31 | 0.46% | CN¥2.75 Million ≈ $402.20K |
CN¥600.98 Million ≈ $87.94 Million |
-0.93pp |
| 2000-12-31 | 1.39% | CN¥8.30 Million ≈ $1.21 Million |
CN¥597.05 Million ≈ $87.37 Million |
-0.14pp |
| 1999-12-31 | 1.53% | CN¥7.32 Million ≈ $1.07 Million |
CN¥479.49 Million ≈ $70.16 Million |
-0.27pp |
| 1998-12-31 | 1.80% | CN¥11.33 Million ≈ $1.66 Million |
CN¥631.05 Million ≈ $92.34 Million |
+0.52pp |
| 1997-12-31 | 1.27% | CN¥9.46 Million ≈ $1.38 Million |
CN¥743.86 Million ≈ $108.85 Million |
+0.43pp |
| 1996-12-31 | 0.84% | CN¥6.46 Million ≈ $944.57K |
CN¥766.94 Million ≈ $112.23 Million |
-6.37pp |
| 1995-12-31 | 7.21% | CN¥62.10 Million ≈ $9.09 Million |
CN¥861.03 Million ≈ $126.00 Million |
-0.17pp |
| 1994-12-31 | 7.38% | CN¥61.36 Million ≈ $8.98 Million |
CN¥831.10 Million ≈ $121.62 Million |
-5.30pp |
| 1993-12-31 | 12.69% | CN¥99.25 Million ≈ $14.52 Million |
CN¥782.34 Million ≈ $114.48 Million |
-- |
About Nanhua Bio Medicine Co Ltd
Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. It operates in two segments, Biomedicine, and Energy Saving and Environmental Protection. The Biomedicine segment provides stem cell and immune cell testing, storage, and technical services; as well as sales of biopharmaceutical products, such as beauty products, health supplements, and air purifiers. The Energy Saving and… Read more